IQX Limited

iQX Limited (NSX:IQX) today announced it has received a worldwide license from Harvard's Office of Technology Development to commercialise diagnostic technology developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University.

iQX Limited (NSX:IQX) has filed an application with the U.S Food and Drug Administration (FDA) for Breakthrough Device Designation.

iQX Limited (NSX:IQX), on behalf of Life Science Biosensor Diagnostics Pty Ltd (LSBD), in which IQX holds 19% equity position, today announced the successful completion of a clinical validation study showcasing the efficacy of its rapid SARS-Cov-2 Antibody test.

iQX Limited (NSX:IQX) is pleased to announce that OncoTEX Inc has received licensing for a gold compound platform technology that induces the body's immune system to destroy cancer cells.

iQX Limited (NSX:IQX), on behalf of Life Science Biosensor Diagnostics Pty Ltd (LSBD), in which IQX holds 19% equity position, that LSBD's subsidiary GBS today announced it has been awarded a AUD $6.3 million, Australian Federal Government scientific grant.

iQX Limited (iQX Ltd) (NSX:IQX) would like to announce that Life Science Biosensor Diagnostics Pty Ltd (LSBD) in which iQX Ltd holds a 19% equity position, has received approval from the Harvard Longwood campus Institutional Review Board (IRB) to commence a clinical validation study to test patient samples from a COVID-19 repository.

Notice is hereby given that an Extraordinary General Meeting (EGM) of iQX Limited (NSX:IQX) will be held at ParkRoyal Darling Harbour at 10.00am (AEST) on Tuesday 14 July 2020.

iQX Limited (iQX Ltd) (NSX:IQX) would like to announce a collaboration agreement between the Wyss Institute for Biologically Inspired Engineering, Harvard University, and Life Science Biosensor Diagnostics Pty Ltd (LSBD), in which iQX Ltd holds a 19% equity position.